Skip to content
10-Q

Quarterly Report

Artiva Biotherapeutics, Inc. ARTV

0001193125-26-213242

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 24.72M sh
Shares Diluted Q1 2026 · Mar 31, 2026 24.68M sh
Shares Diluted Q1 2026 · Mar 31, 2025 24.34M sh
Capex Q1 2026 · Mar 31, 2026 $242K
Capex Q1 2026 · Mar 31, 2025 $511K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$20.95M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$19.84M
Short Term Investments Q1 2026 · Mar 31, 2026 $65.83M
Short Term Investments Q1 2026 · Dec 31, 2025 $81.31M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $20.96M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $26.7M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $30.4M
Stockholders Equity Q1 2026 · Mar 31, 2026 $87.85M
Stockholders Equity Q1 2026 · Dec 31, 2025 $109.97M
Stockholders Equity Q1 2026 · Mar 31, 2025 $168.78M
Stockholders Equity Q1 2026 · Dec 31, 2024 $186.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.88M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $18.11M
Total Liabilities Q1 2026 · Dec 31, 2025 $20.97M
Current Assets Q1 2026 · Mar 31, 2026 $88.74M
Current Assets Q1 2026 · Dec 31, 2025 $112.67M
Total Assets Q1 2026 · Mar 31, 2026 $105.96M
Total Assets Q1 2026 · Dec 31, 2025 $130.94M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.95
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.83
Eps Basic Q1 2026 · Mar 31, 2026 −$0.95
Eps Basic Q1 2026 · Mar 31, 2025 −$0.83
Sga Expense Q1 2026 · Mar 31, 2026 $5.12M
Sga Expense Q1 2026 · Mar 31, 2025 $5.12M
Rd Expense Q1 2026 · Mar 31, 2026 $19.31M
Rd Expense Q1 2026 · Mar 31, 2025 $17.05M
Net Income Q1 2026 · Mar 31, 2026 −$23.52M
Net Income Q1 2026 · Mar 31, 2025 −$20.31M
Operating Income Q1 2026 · Mar 31, 2026 −$24.43M
Operating Income Q1 2026 · Mar 31, 2025 −$22.17M